Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07252336 | A Multicenter Study of CAR-T Cells in Primary Ph+All | recruiting | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 / Phase 3 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Dec 4, 2025 | clinicaltrials |
| NCT04844528 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259161 | Modified Conditioning Regimen for CML-BP | not yet recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07256210 | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 | 15 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06316427 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07070323 | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies(nanobody CD5) | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07244406 | Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | recruiting | Phase 2 | 59 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05566054 | Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia | recruiting | Phase 2 | 92 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05940961 | Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL | recruiting | Phase 2 | 42 | Sheng-Li Xue, MDOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07238712 | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor(APTBCy) | recruiting | Phase 2 | 60 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06532552 | Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 2 | 172 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04070443 | Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase(TIPI) | active not recruiting | Phase 2 | 170 | Centre Leon BerardOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06530576 | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06716658 | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07232953 | Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia(FT14) | active not recruiting | Phase 2 | 82 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | recruiting | Phase 2 | 240 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy(RAFA) | recruiting | Phase 2 | 70 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04817241 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | active not recruiting | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | recruiting | Phase 2 | 78 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02323867 | Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies(AB-CliniMACs) | active not recruiting | Phase 2 | 140 | Children's Hospital of PhiladelphiaOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02756962 | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | active not recruiting | Phase 2 | 107 | Washington University School of MedicineOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 | clinicaltrials |
| NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | not yet recruiting | Phase 2 | 27 | University Hospital TuebingenOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT06265584 | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 56 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06315309 | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 29 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT07039877 | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients | recruiting | Phase 2 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT02917720 | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients(NAUT) | active not recruiting | Phase 2 | 75 | European LeukemiaNetNETWORK | 2 | Sep 22, 2025 | clinicaltrials |
| NCT05192889 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | active not recruiting | Phase 1 / Phase 2 | 35 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04258943 | Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 60 | Children's Oncology GroupNETWORK | 8 | Sep 18, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART E) | not yet recruiting | Phase 1 / Phase 2 | 42 | Princess Maxima Center for Pediatric OncologyOTHER | 0 | Sep 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2025source: clinicaltrials